Holen Sie sich die Stockscreener-App
0.4773
3.50%
-0.0173
Schlusskurs vom Vortag:
$0.4946
Offen:
$0.4892
24-Stunden-Volumen:
244.19K
Relative Volume:
0.87
Marktkapitalisierung:
$37.58M
Einnahmen:
$9.53M
Nettoeinkommen (Verlust:
$-44.61M
KGV:
-0.5245
EPS:
-0.91
Netto-Cashflow:
$-38.32M
1W Leistung:
-14.93%
1M Leistung:
-29.90%
6M Leistung:
-24.67%
1J Leistung:
-58.13%
1-Tages-Spanne:
$0.4753
$0.508
1-Wochen-Bereich:
$0.4747
$0.5898
52-Wochen-Spanne:
$0.4747
$1.75
Cue Biopharma Inc Stock (CUE) Company Profile
Firmenname
Cue Biopharma Inc
Sektor
Branche
Telefon
617-949-2680
Adresse
40 GUEST STREET, BOSTON, MA
Vergleichen Sie CUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.4773 | 38.94M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-13 | Eingeleitet | Jefferies | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-11-21 | Eingeleitet | Piper Sandler | Overweight |
| 2022-01-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-03 | Eingeleitet | Craig Hallum | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-04-09 | Eingeleitet | Stifel | Buy |
| 2020-01-28 | Eingeleitet | BTIG Research | Buy |
| 2020-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Cue Biopharma Inc Aktie (CUE) Neueste Nachrichten
Does Cue Biopharma Inc (CUE) offer a good opportunity for investors? - Setenews
Cue Biopharma (CUE) Price Target Increased by 25.00% to 5.10 - Nasdaq
Will Cue Biopharma Inc. stock continue upward momentum2025 Price Momentum & Fast Gain Stock Trading Tips - Newser
Is Cue Biopharma Inc. stock a safe investment in uncertain marketsDip Buying & Stepwise Trade Signal Implementation - Newser
How Cue Biopharma Inc. stock reacts to inflationary pressuresTrade Signal Summary & Real-Time Volume Triggers - Newser
Is Cue Biopharma Inc. (1UC) stock dividend growth reliableSwing Trade & Community Consensus Picks - Newser
Is Cue Biopharma Inc. (1UC) stock testing key supportStop Loss & Long-Term Safe Investment Ideas - Newser
What Wall Street predicts for Cue Biopharma Inc. stock price2025 Breakouts & Breakdowns & Safe Entry Zone Identification - Newser
Will Cue Biopharma Inc. (1UC) stock benefit from infrastructure billQuarterly Earnings Report & Long-Term Capital Growth Strategies - Newser
How Cue Biopharma Inc. (1UC) stock moves in volatile trading sessionsOil Prices & High Conviction Buy Zone Alerts - Newser
Can Cue Biopharma Inc. stock rebound after recent weakness2025 Volume Leaders & Technical Buy Zone Confirmation - BỘ NỘI VỤ
Is Cue Biopharma Inc (CUE) positioned for future growth? - Setenews
Will Cue Biopharma Inc. stock benefit from AI adoptionMarket Risk Summary & Community Supported Trade Ideas - moha.gov.vn
[Form 4] Cue Biopharma, Inc. Insider Trading Activity - Stock Titan
Cue Biopharma Releases Updated Corporate Presentation - TipRanks
[8-K] Cue Biopharma, Inc. Reports Material Event | CUE SEC FilingForm 8-K - Stock Titan
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates - MSN
Can Cue Biopharma Inc. stock resist market sell offsGlobal Markets & Smart Swing Trading Alerts - newser.com
Will Cue Biopharma Inc. stock recover faster than peers2025 Top Gainers & Risk Controlled Daily Trade Plans - newser.com
Is Cue Biopharma Inc. stock dividend yield sustainableWeekly Trade Report & Verified Chart Pattern Signals - newser.com
Cue Biopharma Announces CMO Departure - TipRanks
Cue Biopharma Announces Departure of Chief Medical Officer - TradingView
Cue Biopharma, Inc. Announces Termination of Matteo Levisetti as Chief Medical Officer, Effective November 28, 2025 - MarketScreener
Why Cue Biopharma Inc. (1UC) stock benefits from AI revolutionEarnings Beat & Reliable Trade Execution Plans - newser.com
Is Cue Biopharma Inc. stock trading at a premium valuationPortfolio Risk Report & Risk Adjusted Buy/Sell Alerts - newser.com
Will Cue Biopharma Inc. (1UC) stock deliver compounding returns2025 Market WrapUp & Risk Controlled Daily Plans - newser.com
Why Cue Biopharma Inc. (1UC) stock could be next leader2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
How Cue Biopharma Inc. stock performs in rate cut cycles2025 Geopolitical Influence & Advanced Swing Trade Entry Plans - newser.com
Can Cue Biopharma Inc. (1UC) stock expand revenue streams2025 Market Overview & Smart Investment Allocation Insights - newser.com
What dividend safety score for Cue Biopharma Inc. stockJuly 2025 Analyst Calls & Community Verified Watchlist Alerts - newser.com
Is Cue Biopharma Inc. stock gaining market shareWeekly Stock Analysis & Free Safe Capital Growth Stock Tips - newser.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Is Cue Biopharma Inc. stock attractive for hedge fundsBond Market & Fast Entry Momentum Trade Alerts - newser.com
Trend analysis for Cue Biopharma Inc. this week2025 Market WrapUp & Safe Capital Allocation Plans - newser.com
Finanzdaten der Cue Biopharma Inc-Aktie (CUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):